about
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the pote...
Read More
2.13
0.03
(1.43%)
351.1K
XNAS Volume
XNAS 26 Sep, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Climb Bio Inc. is on 29 Sep 2025 for the purpose of CLYM116 and the IgA Nephropathy (IgAN) Opportunity
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Climb Bio Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..